Small-molecule inhibitors of lysine methyltransferases SMYD2 and SMYD3: current trends.
SMYD2
SMYD3
chemical probes
protein methyltransferases
small-molecule inhibitors
structure-based drug discovery
Journal
Future medicinal chemistry
ISSN: 1756-8927
Titre abrégé: Future Med Chem
Pays: England
ID NLM: 101511162
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
pubmed:
19
4
2019
medline:
6
2
2020
entrez:
19
4
2019
Statut:
ppublish
Résumé
Lysine methyltransferases SMYD2 and SMYD3 are involved in the epigenetic regulation of cell differentiation and functioning. Overexpression and deregulation of these enzymes have been correlated to the insurgence and progression of different tumors, making them promising molecular targets in cancer therapy even if their role in tumors is not yet fully understood. In this light, selective small-molecule inhibitors are required to fully understand and validate these enzymes, as this is a prerequisite for the development of successful targeted therapeutic strategies. The present review gives a systematic overview of the chemical probes developed to selectively target SMYD2 and SMYD3, with particular focus on the structural features important for high inhibitory activity, on the mode of inhibition and on the efficacy in cell-based and in
Identifiants
pubmed: 30998113
doi: 10.4155/fmc-2018-0380
doi:
Substances chimiques
Enzyme Inhibitors
0
Small Molecule Libraries
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
SMYD2 protein, human
EC 2.1.1.43
SMYD3 protein, human
EC 2.1.1.43
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM